Advanced search
Publication Cover
The American Journal of Drug and Alcohol Abuse
Encompassing All Addictive Disorders
Volume 50, 2024 - Issue 1
Submit an article Journal homepage
736
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Opioid overdose after extended-release buprenorphine injection: a case report

Raluca IsenbergDivision of Addiction Medicine, Cooper University Healthcare, Camden, NJ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0006-4585-620XView further author information
ORCID Icon
Pages 123-124 | Received 12 Jul 2023, Accepted 03 Dec 2023, Published online: 22 Jan 2024

References

  • Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. Drug Alcohol Depend. 2018;193:117–23. doi:10.1016/j.drugalcdep.2018.09.007. Epub 20181012PubMed PMID: 30359928.
  • Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther. 2020;9:41–54. doi:10.1007/s40122-019-00143-6. Epub 20200128PubMed PMID: 31994020; PubMed Central PMCID: PMCPMC7203271.
  • Sublocade. Package insert. Indivior Inc; 2021 [accessed 2023 Apr 21]. https://www.sublocade.com/Content/pdf/prescribing-information.pdf.
  • Ganetsky VS, Salzman M, Carroll G, Heil J, Sutton J, Visioli VM, Currie S, Schmidt R, Baston KE, Haroz R, et al. Hospital-initiated extended-release injectable buprenorphine using a novel reallocation initiative from an outpatient addiction medicine clinic. J Addict Med. 2023;17:108–10. doi:10.1097/ADM.0000000000001038. Epub 20220927PubMed PMID: 36166670.
  • Qian G, Rao I, Humphreys K, Owens DK, Brandeau ML. Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2023;243:109762. doi:10.1016/j.drugalcdep.2022.109762. Epub 20221230PubMed PMID: 36621198; PubMed Central PMCID: PMCPMC9852082.
  • Peckham AM, Kehoe LG, Gray JR, Wakeman SE. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: a retrospective case series. J Subst Abuse Treat. 2021;126:108316. doi:10.1016/j.jsat.2021.108316. Epub 20210202. PubMed PMID: 34116808.
  • Administration USFD. FDA approves new buprenorphine treatment option for opioid use disorder. 2023; [accessed 2023 Aug 29]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder.
  • Pennsylvania Attorney General Josh Shapiro. Fentanyl report. 2022 May 23. 2022-05-23-OAG-Fentanyl-Report.pdf (attorneygeneral.gov).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.